netFormulary Leicestershire Health Community NHS
Medicines Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
Chapter Links...
 Details...
05.03  Expand sub section  Antiviral drugs
05.03.01  Expand sub section  HIV infection
05.03.01  Expand sub section  Nucleoside reverse transcriptase inhibitors
Abacavir
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
 
   
Abacavir and Lamivudine (Kivexa®)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Bictegravir, Emtricitabine and Tenofovir Alafenamide (Biktarvy®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red

High cost drug excluded to tariff
Restricted, to be used in line with NHSE policy only

 
   
Didanosine
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Efavirenz, Emtricitabine and Tenofovir Disoproxil (Atripla®)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff  
   
Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide  (Genvoya®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff  
Link  MHRA advice: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
Link  MHRA Advice: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure
Link  NHSE Policy: Tenofovir Alafenamide
   
Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Disoproxil  (Stribild®)
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
 
Link  MHRA advice: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
Link  MHRA Advice: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure
Link  NHSE Policy: Stribild
   
Emtricitabine
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Emtricitabine and Tenofovir Alafenamide (Descovy®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High cost drug excluded to tariff
Restricted, to be used in line with NHSE policy only 
Link  NHSE Policy: Tenofovir Alafenamide
   
Emtricitabine, Rilpivirine and Tenofovir Alafenamide (Odefsey®)
View adult BNF View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High cost therapy excluded to tarrif
Restricted, to be used in line with NHSE policy only 
Link  NHSE Policy: Tenofovir Alafenamide
   
Emtricitabine, Rilpivirine and Tenofovir Disoproxil  (Eviplera®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
Only for those intolerant or non responsive to Atripla 
   
Lamivudine
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
Also used in treatment of Hepatitis B, commissioned by NHSE in line with NICE CG165 only
 
Link  NICE CG165: Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults
   
Tenofovir Disoproxil
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Tenofovir Disoproxil and Emtricitabine (Truvada®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Drug excluded to tariff  
   
Zidovudine
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Zidovudine and Lamivudine
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
Generic combination has a lower cost than the individual components prescribed separately 
   
Darunavir, Cobicistat, Emtricitabine and tenofovir alafenamide (Symtuza®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
NHS England

High cost drug excluded to tariff. Restricted, to be used in line with NHSE policy only

 
Link  NHSE Commissioning Policy: Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection
   
05.03.01  Expand sub section  Protease inhibitors
Atazanavir
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Atazanavir with Cobicistat (Evotaz®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Darunavir with Cobicistat (Rezolsta® )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
 
Link  MHRA Advice: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
   
Fosamprenavir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Drug excluded to tariff 
   
Lopinavir with Ritonavir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine

High Cost Drug excluded to tariff

 
Link  MHRA advice: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
   
Ritonavir
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
Link  MHRA advice: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
   
Tipranavir
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
Third line therapy 
   
Darunavir
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
2nd line Protease Inhibitor (PI) in patients who have failed at least one PI containing regimen. Recommended to be used in preference to tipranavir where both are an option. 
   
05.03.01  Expand sub section  Other antiretrovirals to top
Enfuvirtide
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Drug excluded to tariff 
   
Raltegravir
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff 
   
Cobicistat
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

Pharmacoenhancer
High Cost Therapy excluded to tariff
For use in line with NHSE policy only

 
Link  MHRA advice: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
Link  NHSE Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
   
Dolutegravir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine

High Cost Therapy excluded to tariff
Supported in line with NHSE policy only. 

MHRA Safety alert: Do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception

 
Link  Dolutegravir (Tivicay, Triumeq, Juluca): signal of increased risk of neural tube defects
Link  NHSE Clinical Commissioning Policy: Dolutegravir
   
Dolutegravir, Abacavir and Lamivudine (Triumeq®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine

High Cost Therapy excluded to tariff. Supported in line with NHSE policy only.

MHRA Safety alert: Do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception

 
Link  Dolutegravir (Tivicay, Triumeq, Juluca): signal of increased risk of neural tube defects
Link  NHSE Clinical Commissioning Policy
   
Maraviroc
View adult BNF View SPC online
Restricted Drug Restricted
Red
High Cost Medicine
High Cost Therapy excluded to tariff
For use in treatment experienced adult patients infected with only CCR5-tropic HIV-1 virus. 
   
05.03.02.02  Expand sub section  Cytomegalovirus infrection
 note  Cidofovir, Foscarnet, Ganciclovir and Valganciclovir are high cost drugs excluded to tariff commissioned by NHSE in line with Trust guidelines for Cytomegalovirus infection.
05.03.03  Expand sub section  Viral hepatitis
Daclatasvir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA only
Blueteq prior approval required before initiation



Date of entry of decision to formulary: February 2016

 
Link  NICE TA 364: Daclatasvir for treating chronic hepatitis C
   
Dasabuvir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist use in Hepatitis C
NHSE commissioned in line with NICE TA 365
Blueteq prior approval required before intiation
Date of entry of decision to Formulary: March 2016

 
Link  NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
   
Elbasvir and grazoprevir (Zepatier®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist use in Hepatitis C
NHSE commissioned in line with NICE TA 413
Blueteq prior approval required before initiation
Date of entry of decision to formulary: January 2017

 
Link  NICE TA 413: Elbasvir–grazoprevir for treating chronic hepatitis C
   
Entecavir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Specialist prescribing in Hepatitis B
Commissioned by NHSE in line with NICE TA 153 only 
Link  NICE TA 153: Entecavir for the treatment of chronic hepatitis B
   
Glecaprevir and pibrentasvir (Maviret®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Specialist prescribing for hepatitis C.
NHSE Commissioned in line with NICE TA 499 only. 
Blueteq prior approval required before initiation

Date of entry of decision to Formulary: February 2018

 
Link  NICE TA 499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
   
Ledipasvir and sofosbuvir  (Harvoni®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA only
Blueteq prior approval required before initiation

Date of entry of decision to formulary: February 2016

 
Link  NICE TA 363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
   
Ombitasvir, paritaprevir, and ritonavir  (Viekirax®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
NHSE commissioned in line with NICE TA only with or without Dasabuvir
Blueteq prior approval required before initiation


Date of entry of decision to formulary: February 2016

 
Link  NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
   
Simeprevir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA only.

Genotype 4 patients require Blueteq prior approval before initiation

Date decision added to Formulary: May 15

 
Link  NICE TA 331: Simeprevir for chronic Hepatitis C
   
Sofosbuvir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
NHSE commissioned in line with NICE TA only
Blueteq prior approval required before initiation

Date decision added to Formulary: May 15

 
Link  NICE TA 330: Sofosbuvir for chronic Hepatitis C
   
Sofosbuvir, velpatasvir, voxilaprevir (Vosevi®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C

NHSE commissioned in line with NICE TA 507 only 
Blueteq prior approval required before initiation 

Date of entry of decision to formulary: May 2018

 
Link  NICE TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
   
Sofosbuvir/valpatasvir (Epclusa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
NHSE commissioned in line with NICE TA only
Blueteq prior approval required before initiation

Date decision added to Formulary: March 17

 
Link  NICE TA 430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
   
Boceprevir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Specialist prescribing in Hepatitis C
Commissioned by NHSE in line with NICE TA 253 only

Date of entry of decision to Formulary: May 2012

Use superceded by newer drugs for Hepatitis C

Blueteq prior approval required before initiation

 
Link  NICE TA 253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
   
Telaprevir
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
NHS England
BlueTeq

Specialist prescribing in Hepatitis C
High cost drug excluded to tariff. Commissioned by NHSE in line with NICE TA 252 only

Date of entry of decision to Formulary: May 2012

Use superceded by newer drugs for Hepatitis C

 
Link  NICE TA 252:Telaprevir for the treatment of genotype 1 chronic hepatitis C
   
05.03.05  Expand sub section  Respiratory syncytial virus
Palivizumab (Synagis®)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
NHS England
BlueTeq

Respiratory syncytial virus (RSV) prophylaxis
High cost drug excluded to tariff commissioned by NHSE
Supported in line with JVCI guidance

From 16/17 season Blueteq prior approval required before initiation

 
   
Ribavirin
View adult BNF View SPC online
Restricted Drug Restricted
Red
High cost drug excluded to tariff commissioned by NHSE
Supported in line with NICE TA 75, 106, 200 
Link  NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Link  NICE TA 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Link  TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
   
 ....
 Non Formulary Items
Dolutegravir, Rilpivirine  (Juluca®)

View adult BNF View SPC online Track Changes
Non Formulary
Black

Not yet reviewed

 
Indinavir

View adult BNF View SPC online
Non Formulary
Black
 
Nelfinavir

View adult BNF View SPC online
Non Formulary
Black
 
Saquinavir

View adult BNF View SPC online
Non Formulary
Black
 
Stavudine

View adult BNF View SPC online
Non Formulary
Black
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Black

Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety. All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry   

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).  

Amber SCA

Drugs which would initially be prescribed by a hospital specialist and then by a GP where full agreement to share the care of each specific patient has been reached under a LMSG Shared Care Agreement (SCA). Specific patient monitoring or intervention required.   

Amber Simple

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.  

Green Conditional

Drugs for which GPs are able to take full responsibility for prescribing and monitoring subject to specified conditions e.g. prescribing in line with agreed LMSG guidance or able to demonstrate suitable competence see comments under individual entries.   

Green

Drugs for which GPs would normally take full responsibility for prescribing and monitoring. Drugs included in this list have been specifically considered by LMSG.   

netFormulary